Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Tuesday 21 December, 2021

SkinBioTherapeutics

Annual General Meeting 2021 - Change of Venue

RNS Number : 3762W
SkinBioTherapeutics PLC
21 December 2021
 

21 December 2021

 

SkinBioTherapeutics plc

   
 

Annual General Meeting 2021 - Change of Venue
 

SkinBioTherapeutics plc (the "Company") announced its full year audited results for the year to 30 June 2021 on 30 November 2021, including notice that the Company's Annual General Meeting ("AGM") would be held at The Core, Bath Lane, Newcastle Helix, Newcastle upon Tyne, NE4 5TF on 23 December 2021 at 11.00 am.

 

As set out in the notes to the Notice of Annual General Meeting included in the Annual Report for the year ended 30 June 2021 published on 30 November 2021, shareholders have been asked not to attend the meeting and to appoint the Chairman of the meeting as their proxy to attend and vote at the meeting. In respect of the evolving Coronavirus (COVID-19) situation and in accordance with the Company's articles of association, the Board has resolved that the venue of the AGM will be moved to 21 College Court, Macclesfield, SK11 8HN.

 

All other details as advised in the Notice of Annual General Meeting remain the same.

 

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis 

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFLFLVFDLLFIL

a d v e r t i s e m e n t